Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zile

Showing results (1031-1040 of 1,060) with videos related to

Pageof 106
Sort By:
European Journal of Public Health|July 1, 2024
Socioeconomic disparities in changes to preterm birth and stillbirth rates during the first year of the COVID-19 pandemic: a study of 21 European countriesJennifer Zeitlin, Marianne Philibert, Henrique Barros, et al.
The Journal of Experimental Medicine|January 18, 2018
Cardiac macrophages promote diastolic dysfunctionMaarten Hulsmans, Hendrik B Sager, Jason D Roh, et al.
European Journal of Heart Failure|May 16, 2023
Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy-associated genes: A subgroup analysis of the PARADIGM-HF trialAna Barat, Chien-Wei Chen, Natasha Patel-Murray, et al.
European Heart Journal|August 15, 2021
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fractionAlice M Jackson, Pardeep S Jhund, Inder S Anand, et al.
American Heart Journal|August 23, 2018
Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trialMichael J Mack, William T Abraham, JoAnn Lindenfeld, et al.
European Journal of Heart Failure|August 31, 2024
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Alasdair D Henderson, Li Shen, et al.
Circulation|June 6, 2024
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HFPooja Dewan, Li Shen, João Pedro Ferreira, et al.
Circulation|October 21, 2024
Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HFLi Shen, Pooja Dewan, João Pedro Ferreira, et al.
Journal of the American College of Cardiology|September 1, 2022
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection FractionJawad H Butt, Pooja Dewan, Pardeep S Jhund, et al.
JACC. Heart Failure|July 15, 2019
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialAlvin Chandra, Muthiah Vaduganathan, Eldrin F Lewis, et al.
Pageof 106

Showing results (1031-1040 of 1,060) with videos related to

Sort By:
Pageof 106
European Journal of Public Health|July 1, 2024
Socioeconomic disparities in changes to preterm birth and stillbirth rates during the first year of the COVID-19 pandemic: a study of 21 European countriesJennifer Zeitlin, Marianne Philibert, Henrique Barros, et al.
The Journal of Experimental Medicine|January 18, 2018
Cardiac macrophages promote diastolic dysfunctionMaarten Hulsmans, Hendrik B Sager, Jason D Roh, et al.
European Journal of Heart Failure|May 16, 2023
Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy-associated genes: A subgroup analysis of the PARADIGM-HF trialAna Barat, Chien-Wei Chen, Natasha Patel-Murray, et al.
European Heart Journal|August 15, 2021
Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fractionAlice M Jackson, Pardeep S Jhund, Inder S Anand, et al.
American Heart Journal|August 23, 2018
Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trialMichael J Mack, William T Abraham, JoAnn Lindenfeld, et al.
European Journal of Heart Failure|August 31, 2024
Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Alasdair D Henderson, Li Shen, et al.
Circulation|June 6, 2024
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HFPooja Dewan, Li Shen, João Pedro Ferreira, et al.
Circulation|October 21, 2024
Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HFLi Shen, Pooja Dewan, João Pedro Ferreira, et al.
Journal of the American College of Cardiology|September 1, 2022
Sacubitril/Valsartan and Frailty in Patients With Heart Failure and Preserved Ejection FractionJawad H Butt, Pooja Dewan, Pardeep S Jhund, et al.
JACC. Heart Failure|July 15, 2019
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialAlvin Chandra, Muthiah Vaduganathan, Eldrin F Lewis, et al.
Pageof 106